Advanced Neuromodulation Systems
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for the company's totally implanted pulse generator (IPG) spinal cord stimulation for relief of chronic pain of the trunk will be submitted to FDA later this month, ANS announces April 4. Separately, the company will continue to appeal the agency's Feb. 23 denial of its petition to downclassify the SCS IPG from Class III to Class II (1"The Gray Sheet" March 5, 2001, p. 10)
You may also be interested in...
CDRH Shocks ANS, Denies Downclassification of Spinal Cord Stimulator
FDA inspections of design controls under the Quality Systems Regulation do not provide enough assurance against device failure to allow the downclassification of the Class III totally implanted spinal cord stimulator (SCS) for pain relief, the agency maintains in a Feb. 23 letter to Advanced Neuromodulation Systems.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.